<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462589</url>
  </required_header>
  <id_info>
    <org_study_id>SY008001</org_study_id>
    <nct_id>NCT03462589</nct_id>
  </id_info>
  <brief_title>Single Ascending Oral Doses of SY-008 in Healthy Subjects</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Dose Escalated Tolerance and Pharmacokinetic / Pharmacodynamic Studies of SY-008 Capsules Administered by Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ⅰ，single-center, randomized, double-blinded, placebo-controlled, single
      ascending dose trial of SY-008 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dosed tolerability, pharmacokinetic /
      pharmacodynamic study of a single oral SY-008 capsule for Chinese healthy subjects. Plan to
      screening total of 54 healthy subjects ， dividing them into 6 dose groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>7 days</time_frame>
    <description>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>area under curve (AUC) of SY-008 following oral administration of single ascending dose</measure>
    <time_frame>3 days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of SY-008 following oral administration of single ascending dose</measure>
    <time_frame>3 days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of SY-008 following oral administration of single ascending dose</measure>
    <time_frame>3 days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (Clearance rectified) of SY-008 following oral administration of single ascending dose</measure>
    <time_frame>3 days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose levels following single dose of SY-008</measure>
    <time_frame>24 hours</time_frame>
    <description>FPG AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion following single dose of SY-008</measure>
    <time_frame>3 days</time_frame>
    <description>insulin changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide secretion following single dose of SY-008</measure>
    <time_frame>6 hours</time_frame>
    <description>C-peptide change</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>SY-008 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-008 (2~30mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-008 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-008 (2~30mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-008 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-008 (2~30mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-008 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-008 (2~30mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-008 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-008 (2~30mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-008 matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>from 6mg to 30mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-008</intervention_name>
    <description>The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.</description>
    <arm_group_label>SY-008 dose 1</arm_group_label>
    <arm_group_label>SY-008 dose 2</arm_group_label>
    <arm_group_label>SY-008 dose 3</arm_group_label>
    <arm_group_label>SY-008 dose 4</arm_group_label>
    <arm_group_label>SY-008 dose 5</arm_group_label>
    <arm_group_label>SY-008 matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gender: Male and female, gender balance.

          2. Age: 18-65 years old (including the boundary values).

          3. Weight ≥50kg and 19kg / m2 ≤ BMI ≤ 28kg / m2 [BMI = body weight (kg) / height 2 (m2).

          4. fasting plasm glucose (FPG): 3.9-6.1mmol / L (excluding the boundary values).

          5. glycosylated hemoglobin (HbA1c) &lt;6.5%.

          6. healthy subjects determined by medical history, physical examination,
             electrocardiogram and laboratory tests. Test results within the normal range for the
             population or investigator site, or with abnormalities deemed clinically insignificant
             by the investigator.

          7. have venous access sufficient to allow blood sampling as per the protocol.

          8. have given written informed consent approved by sponsors and the ethical review board
             governing the site.

          9. are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures.

        Exclusion Criteria:

          1. are investigator site personnel directly affiliated with this study and their
             immediate families. Immediate family is defined as a spouse, parent, child or sibling,
             whether biological or legally adopted.

          2. within 3 months prior to screening, complete or withdraw a clinical study, or are
             currently conducting a clinical study. Or are concurrently enrolled in any other type
             of medical research judged not to be scientifically or medically compatible with this
             study.

          3. have previously completed or withdrawn from this study.

          4. 2h postprandial plasm glucose (2hPPG) ≥7.8 mmol / L（Test on -1 Day）.

          5. have known allergies to compounds related to SY-008 capsules or multiple drug
             allergies, or have been treated with SGLT-1(sodium-glucose cotransporter-1) inhibitors
             in 1 year.

          6. have significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal (such as hemorrhoids, inflammation of GI tract, tumor, history of
             surgery, habitual bellyache or diarrheal disorders, other motility disorders),
             endocrine, or neurological disorders capable of significantly altering the absorption,
             metabolism, or elimination of drugs or of constituting a risk when taking the study
             medication or interfering with the interpretation of data.

          7. have a history of alcohol abuse or drug abuse.

          8. show evidence or test positive on any of the following: hepatitis B virus surface
             antigen (HBsAg), hepatitis C virus antibody (HCV), Treponema pallidum antibody (TP),
             HIV (HIV1 + 2) antibody.

          9. have donated blood of 400 mL or more in the last 3 months or provided any blood
             donation within the last month from screening.

         10. are subjects who have an average weekly alcohol intake that exceeds 21 units per week
             (males) and 14 units per week (females; 1 unit = 12 oz or 360 mL of beer; 5 oz or 150
             mL of wine; 1.5 oz or 45 mL of distilled spirits) or are subjects unwilling to stop
             alcohol consumption 24 hours prior to dosing until the completion of each inpatient
             study period.

         11. consume more than 10 cigarettes per day or the equivalent, or are unable or unwilling
             to refrain from nicotine during the study.

         12. intend to use over-the-counter or prescription medications within 14 days prior to
             dosing or during the study.

         13. subjects not agree to use reliable contraceptive methods (hormones or barriers or
             abstinence) during the study period and at least 1 month after administration.

         14. women were positive for blood pregnancy test within 24 hours prior to enrollment.

         15. pregnant or lactating women.

         16. in the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Shao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Frist Affiliated Hospital Of Nanjing Madical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

